FinnCap Reiterates “Buy” Rating for Dechra Pharmaceuticals plc (DPH)
Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating restated by research analysts at FinnCap in a report released on Wednesday. They currently have a GBX 800 ($13.58) target price on the stock. FinnCap’s price objective points to a potential upside of 16.28% from the company’s current price.
Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 2.25% during mid-day trading on Wednesday, hitting GBX 703.50. The stock had a trading volume of 377,707 shares. Dechra Pharmaceuticals plc has a 52 week low of GBX 655.00 and a 52 week high of GBX 755.00. The stock has a 50-day moving average of GBX 704.4 and a 200-day moving average of GBX 692.5. The company’s market cap is £613.5 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Investec raised their price target on shares of Dechra Pharmaceuticals plc from GBX 787 ($13.36) to GBX 842 ($14.29) in a research note on Wednesday, June 11th. They now have a “buy” rating on the stock. Separately, analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Thursday, June 5th. They now have a GBX 850 ($14.43) price target on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of GBX 781 ($13.26).
Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.